News
Stockhead on MSN5h
Neurizon’s ALS drug shows safety and extended survival in open-label extension study
Neurizon Therapeutics has reported positive topline results from an open-label extension study of its lead candidate NUZ-001 ...
The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...
Ansa on MSN19h
Italo-US team in ALS diagnosis breakthrough
ROME, AUG 19 - An Italo-US team of scientists have made a breakthrough in the early diagnosis of amyotrophic lateral ...
By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...
HealthDay on MSN1d
FDA approves ketamine product for surgical pain management
The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management.
Yet another biotech is facing a delay from the FDA as the agency reels from intense staffing cuts. | Yet another biotech is ...
Brooke Eby posted a "dying diary" to describe the feeling of her ALS and progressing paralysis. The 36-year-old TikToker ...
Familial amyotrophic lateral sclerosis (ALS) is an uncommon form of ALS that occurs due to an inherited gene. The disease causes motor neurons to die, which can lead to progressive muscle weakness.
• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback